Login to Your Account

ESO Accounting Changes Could Hurt Biotech Hiring, Bottom Lines

By Randall Osborne

Monday, April 29, 2002
As if implications of the Enron Corp. situation hadn't already messed things up enough for biotechnology (and just about every other sector that uses balance sheets and ledgers), another spawn of the scandal has reared its head for industry leaders to fear and loathe. (BioWorld Financial Watch)

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription